NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Hemotune AG

Hemotune AG

Private
SchlierenHealthcare & Life Scienceshttps://www.hemotune.com/

Last Round

Series B

Extension

Mar 25, 2024

Total Funding Raised

$33.54M

Company Overview

Hemotune AG is a medical devices company that develops a blood purification platform using nanoengineered magnetic beads to selectively remove harmful substances from the bloodstream.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Clinical Trials, Advanced Materials, Precision Medicine

Business Model

B2B

Customer Profile

Hardware + Subscription, Hardware Sales, Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

blood purificationmagnetic nanoparticlesextracorporeal blood treatmentsepsis treatmentmedical deviceimmunomodulationcytokine removalextracorporeal therapymedical nanotechnologyprecision medicinetherapeutic apheresismedical consumablestoxin removalclinical stage company

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hemotune AG Comps

Public and private peers based on sector, stage, and business model.

Hemotune AG comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Hemotune AG Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionMar 25, 2024
Series B ExtensionApr 26, 2022
Series AAug 12, 2020
GrantJul 9, 2020
GrantFeb 1, 2020
Accelerator
Jul 5, 2017

Key People

Founding team and executive leadership

Carlos Andrea Mora

CTO, Head of HR & co-founder

Founding Team

Lukas Langenegger

CEO Co-founder

Founding Team

Hemotune AG Investors

Notable investors and investment history

Hemotune AG investors
InvestorRounds
Gebert Rüf StiftungGrant
EIT HealthGrant, Series A
VP Venture PartnersSeries B Extension
EFI Lake Geneva VenturesSeries B Extension
Wyss ZurichGrant
Belmondo Family OfficeSeries B Extension
InnosuisseGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 25, 2024

    $16M round led by Belmondo Family Office

  • Apr 26, 2022

    $7.6M round led by OCCIDENT.

Hemotune AG Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hemotune AG Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hemotune AG's valuation, stock price, and market status.

Firmographic Details

HeadquartersSchlieren
Employee Range32
Year Founded2017
Last FundingMar 25, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.